Figure 10.

TrxR expression and activity are up-regulated by mTOR inhibitors. (A-C) HCT116 cells were treated with rapamycin (20 µM) or everolimus (20 µM) for indicated time periods and then lysed for Western blot analyses with the indicated antibodies. (D) TrxR activity was measured by the endpoint insulin reduction assay after treated with rapamycin or auranofin alone or their combination. (E) TrxR activity was measured by the endpoint insulin reduction assay after treated with everolimus or auranofin alone or their combination. (F-K) HCT116 cells were treated with rapamycin (20 µM) or everolimus (20 µM) for indicated time periods and then lysed for Western blot analyses with the indicated antibodies. Data from three technical replicates (* p < 0.05, ** p < 0.01).